EcoR1 Capital, LLC
About EcoR1 Capital, LLC’s 13F portfolio
EcoR1 Capital, LLC is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , EcoR1 Capital, LLC reported $2.0B across 31 US-listed positions (). Its largest position is ZYMEWORKS INC (ZYME) at 30% of the reported book, and its ten biggest holdings make up 88% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.
| # | Stock | Price | % of portfolio | Shares | Value |
|---|---|---|---|---|---|
| 1 | NASDAQ: ZYME ZYMEWORKS INC | — — | 30% | 23.0M | $600.4M |
| 2 | NASDAQ: ANAB ANAPTYSBIO INC | — — | 26% | 7.9M | $531.9M |
| 3 | NASDAQ: AKTS AKTIS ONCOLOGY INC | — — | 7.7% | 4.8M | $155.5M |
| 4 | NASDAQ: CGON CG ONCOLOGY INC | — — | 5.3% | 1.5M | $106.2M |
| 5 | NASDAQ: ETON ETON PHARMACEUTICALS INC | — — | 3.9% | 2.2M | $78.6M |
| 6 | NASDAQ: CRSP CRISPR THERAPEUTICS AG | — — | 3.8% | 1.4M | $75.8M |
| 7 | NASDAQ: ORIC ORIC PHARMACEUTICALS INC | — — | 3.6% | 6.7M | $72.9M |
| 8 | NASDAQ: TRAX FIRST TRACKS BIOTHERAPEUTICS | — — | 3.2% | 3.2M | $63.9M |
| 9 | NASDAQ: GLPG LAKEFRONT BIOTHERAPEUTICS NV | — — | 2.5% | 1.7M | $50.0M |
| 10 | NASDAQ: NGNE NEUROGENE INC | — — | 2.0% | 1.3M | $40.0M |
| 11 | NASDAQ: STOK STOKE THERAPEUTICS INC | — — | 1.2% | 735K | $24.0M |
| 12 | NASDAQ: FULC FULCRUM THERAPEUTICS INC | — — | 1.2% | 6.5M | $24.0M |
| 13 | NASDAQ: LEGN LEGEND BIOTECH CORP | — — | 1.1% | 800K | $23.1M |
| 14 | NASDAQ: BBOT BRIDGEBIO ONCOLOGY THERAPEUT | — — | 1.1% | 2.8M | $21.5M |
| 15 | NASDAQ: MBX MBX BIOSCIENCES INC | — — | 1.1% | 389K | $21.4M |
| 16 | NASDAQ: ZBIO ZENAS BIOPHARMA INC | — — | 1.0% | 790K | $20.0M |
| 17 | NASDAQ: ATRA ATARA BIOTHERAPEUTICS INC | — — | 0.9% | 1.6M | $17.8M |
| 18 | NASDAQ: RLAY RELAY THERAPEUTICS INC | — — | 0.6% | 698K | $13.1M |
| 19 | NASDAQ: AURA AURA BIOSCIENCES INC | — — | 0.6% | 1.7M | $11.8M |
| 20 | NASDAQ: ODTX ODYSSEY THERAPEUTICS INC | — — | 0.5% | 556K | $10.4M |
| 21 | NASDAQ: EIKN EIKON THERAPEUTICS INC | — — | 0.5% | 733K | $9.6M |
| 22 | NASDAQ: PHVS PHARVARIS N V | — — | 0.4% | 235K | $8.1M |
| 23 | NASDAQ: ZURA ZURA BIO LTD | — — | 0.3% | 1.2M | $7.0M |
| 24 | NASDAQ: PHAT PHATHOM PHARMACEUTICALS INC | — — | 0.3% | 625K | $6.8M |
| 25 | NASDAQ: NRIX NURIX THERAPEUTICS INC | — — | 0.3% | 270K | $6.6M |
Showing 1–25 of 31 positions on this page reported in this 13F.
- Healthcare88%
- AddedCGONCG ONCOLOGY INC+35.6%$106.2M
- NewTRAXFIRST TRACKS BIOTHERAPEUTICS—$63.9M
- AddedSTOKSTOKE THERAPEUTICS INC+635%$24.0M
- NewFULCFULCRUM THERAPEUTICS INC—$24.0M
- NewLEGNLEGEND BIOTECH CORP—$23.1M
- AddedATRAATARA BIOTHERAPEUTICS INC+1458%$17.8M
- NewAURAAURA BIOSCIENCES INC—$11.8M
- NewODTXODYSSEY THERAPEUTICS INC—$10.4M
- NewPHVSPHARVARIS N V—$8.1M
- NewNRIXNURIX THERAPEUTICS INC—$6.6M
- ReducedMBXMBX BIOSCIENCES INC−50.0%$21.4M
- ReducedRLAYRELAY THERAPEUTICS INC−63.4%$13.1M
- ReducedERASERASCA INC−63.3%$6.0M
- ReducedMREOMEREO BIOPHARMA GROUP PLC−92.5%$318K
- SoldXNCRXENCOR INC−100%—
- SoldIBIOIBIO INC−100%—
- SoldPRLDPRELUDE THERAPEUTICS INC−100%—
- SoldREPLREPLIMUNE GROUP INC−100%—
- SoldJAZZJAZZ PHARMACEUTICALS PLC−100%—
- SoldCNTACENTESSA PHARMACEUTICALS PLC−100%—
Companies where this manager has disclosed a stake of more than 5% of a class of shares, as reported to the SEC on Schedule 13D (activist) or 13G (passive). Figures are as disclosed in each filing — tap a date to open the source document.
| # | Stock | Type | % of class | Shares | Filed |
|---|---|---|---|---|---|
| 1 | ZYME Zymeworks Inc. | 13D | 30.7% | 23.0M | Filed 19 NOV 2025 |
| 2 | — iTeos Therapeutics, Inc. | 13D | 27.9% | 10.7M | Filed 16 MAY 2025 |
| 3 | ATRA Atara Biotherapeutics, Inc. | 13G | 9.9% · 2 classes | 716K | Filed 14 NOV 2025 |
| 4 | MREO Mereo BioPharma Group plc | 13G | 9.4% | 74.5M | Filed 09 JAN 2026 |
| 5 | AKTS Aktis Oncology, Inc. | 13D | 9.1% | 4.9M | Filed 20 JAN 2026 |
| 6 | TRAX First Tracks Biotherapeutics, Inc. | 13G | 9.1% | 3.2M | Filed 22 APR 2026 |
| 7 | FULC Fulcrum Therapeutics, Inc. | 13G | 8.9% | 6.8M | Filed 16 NOV 2026 |
| 8 | ETON Eton Pharmaceuticals, Inc. | 13G | 8.6% · 2 classes | 2.5M | Filed 16 NOV 2026 |
| 9 | QURE uniQure N.V. | 13G | 7.5% | 3.6M | Filed 17 DEC 2024 |
| 10 | ORIC ORIC Pharmaceuticals, Inc. | 13G | 6.9% | 6.7M | Filed 05 AUG 2025 |
| 11 | VYGR Voyager Therapeutics, Inc. | 13G | 6.8% | 4.0M | Filed 17 FEB 2026 |
| 12 | ANRO Alto Neuroscience, Inc. | 13G | 5.8% | 2.2M | Filed 20 JUL 2026 |
Showing all 12 disclosed stakes. 3 last disclosed over a year ago (the holder may since have dropped below 5%).
Reading EcoR1 Capital, LLC’s 13F portfolio
EcoR1 Capital, LLC’s $2.0B 13F book is spread across 31 reported positions and is highly concentrated — its ten largest positions alone are 88% of the portfolio. A book this concentrated means a small group of names drives most of its performance. Its five largest positions are ZYME, ANAB, AKTS, CGON and ETON, led by ZYMEWORKS INC (ZYME) at 30% of the portfolio. The heaviest sector exposure is Healthcare (88%).
What EcoR1 Capital, LLC changed last quarter
Between 2026-03-31 and Q2 2026, EcoR1 Capital, LLC was roughly balanced between buying and selling: it opened 9 new positions and added to 3 more, while trimming 4 and closing 7 outright. Against a 31-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was CG ONCOLOGY INC (CGON), and its biggest reduction was MBX BIOSCIENCES INC (MBX).
What a 13F does and doesn’t reveal
A 13F captures only EcoR1 Capital, LLC’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names EcoR1 Capital, LLC is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.
Frequently asked questions
What is an SEC 13F filing?
A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. EcoR1 Capital, LLC's profile on this page is built directly from those filings.
How current is the 13F data on EcoR1 Capital, LLC's page?
It reflects EcoR1 Capital, LLC's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When EcoR1 Capital, LLC files its next quarterly report, this page refreshes automatically.
Can I see EcoR1 Capital, LLC's complete list of holdings?
This page highlights EcoR1 Capital, LLC's largest positions rather than all 31 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under EcoR1 Capital, LLC's filings.
Does a 13F show everything EcoR1 Capital, LLC owns?
No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of EcoR1 Capital, LLC's book rather than its full strategy or total assets.
Is 13F data investment advice?
No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why EcoR1 Capital, LLC made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.
Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.

